Researchers have confirmed that two novel compound heterozygous mutations in the SLC12A3 gene are pathogenic, leading to loss-of-function in a patient with Gitelman syndrome. The study, which combined clinical assessment with in vitro functional validation, provides critical evidence for classifying variants of uncertain significance. The findings suggest that these specific mutations disrupt the function of the thiazide-sensitive sodium-chloride cotransporter (NCC) through protein misfolding and impaired cellular trafficking.
Gitelman syndrome is a rare autosomal recessive renal tubulopathy characterized by the loss of function in the SLC12A3 gene. This gene encodes the NCC protein, which is essential for sodium and chloride reabsorption in the distal convoluted tubule of the kidney. While the clinical hallmarks of the condition include hypokalemia, metabolic alkalosis, and hypocalciuria, diagnosing the condition can be difficult due to significant clinical and genetic heterogeneity. When patients present with novel variants of uncertain significance, functional validation becomes necessary to confirm their role in the disease mechanism.
The patient in this study was a 6-year-old boy who presented with growth retardation and was found to have severe hypokalemia, recorded at 2.11 mmol/L, alongside metabolic alkalosis and hypocalciuria. These symptoms provided strong clinical evidence for Gitelman syndrome, prompting further investigation through whole-exome sequencing. This analysis identified novel compound heterozygous variants in the SLC12A3 gene: a missense mutation c.908G > A, resulting in p.Gly303Glu, and a frameshift deletion c.2895delT, resulting in p.Tyr966Thrfs*14.
To assess the pathogenicity of these identified variants, the research team conducted functional studies using HEK293T cells. They transfected these cells with either Wild-type (WT) or mutant NCC constructs to observe the impact of the variants on protein behavior. Bioinformatics analysis initially indicated that both mutations affected highly conserved amino acid residues and were likely pathogenic, providing a strong rationale for the subsequent experimental validation.
The researchers utilized immunofluorescence microscopy to examine the subcellular localization of the NCC proteins. While the Wild-type NCC correctly localized to the plasma membrane, both mutant proteins were found to be retained within the endoplasmic reticulum. This pattern of mislocalization is indicative of Class II mutations, where the proteins fail to reach their functional site within the cell due to intracellular retention, thereby preventing normal ion transport.
Complementary Western blot analysis demonstrated that protein levels for both mutants were significantly reduced compared to the Wild-type levels. This reduction suggests that the mutant proteins are unstable and undergo rapid degradation within the cell. The functional assays further confirmed that the presence of these mutant proteins failed to support intracellular ion homeostasis, reinforcing the conclusion that the variants lead to a complete loss of NCC function.
This study confirms that the c.908G > A and c.2895delT variants are indeed pathogenic, acting through mechanisms of protein misfolding, defective trafficking, and accelerated degradation. By establishing the functional consequences of these specific mutations, this research expands the known mutational spectrum of Gitelman syndrome and highlights the essential role of functional analysis in the accurate clinical classification of variants of uncertain significance.
Subject of Research: Genetic and functional analysis of SLC12A3 mutations in Gitelman syndrome
Article Title: Functional characterization of novel compound heterozygous SLC12A3 mutations in a patient with Gitelman syndrome
Article References: Shen, Z., Liu, X., Shen, Z., Gan, Z., Bian, X., Xu, J.-T., Yi, B., Wang, Z., Xiong, F., & Liu, Q. (2026). Functional characterization of novel compound heterozygous SLC12A3 mutations in a patient with Gitelman syndrome. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-026-04623-9
Image Credits: AI Generated
DOI: 10.1186/s13023-026-04623-9
Keywords: Gitelman syndrome, SLC12A3, Renal tubulopathy, Genetic variants, Compound heterozygosity, NCC protein, Hypokalemia, Metabolic alkalosis, Hypocalciuria, Protein trafficking, Endoplasmic reticulum, Functional validation, Whole-exome sequencing, Rare disease, Cellular physiology, Variant of uncertain significance, Nephrology research, Genomic medicine
News Source: Juliet Wilcox. (November 18, 2026). Novel SLC12A3 Mutations Identified in Gitelman Syndrome Case. Scienmag.



